Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this phase II, randomized, double-blind placebo controlled, multi-center study
is to evaluate the safety and efficacy of 10 mg atrasentan in hormone naive subjects as
measured by rate of rise in the PSA (primary objective).